PBE vs. ALKS

Last updated Jun 16, 2026

PBE (Invesco Dynamic Biotechnology & Genome ETF) is Health & Biotech Equities fund tracking the Dynamic Biotech & Genome Intellidex Index (AMEX), while ALKS (Alkermes plc) is a stock. Over the past 10 years, PBE returned 8.90%/yr vs 0.70%/yr for ALKS. A 0.60 correlation means they provide meaningful diversification when combined.

Performance

PBE vs. ALKS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Invesco Dynamic Biotechnology & Genome ETF (PBE) and Alkermes plc (ALKS). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, PBE achieves a 3.32% return, which is significantly lower than ALKS's 58.54% return. Over the past 10 years, PBE has outperformed ALKS with an annualized return of 8.90%, while ALKS has yielded a comparatively lower 0.70% annualized return.

PBE

• 1D: 0.81%
• 1M: 4.85%
• YTD: 3.32%
• 6M: 5.17%
• 1Y: 34.13%
• 3Y*: 10.91%
• 5Y*: 2.31%
• 10Y*: 8.90%

ALKS

• 1D: 0.18%
• 1M: 18.36%
• YTD: 58.54%
• 6M: 57.47%
• 1Y: 48.71%
• 3Y*: 11.28%
• 5Y*: 12.07%
• 10Y*: 0.70%

*Multi-year figures are annualized to reflect compound growth (CAGR)

PBE vs. ALKS - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
PBE Invesco Dynamic Biotechnology & Genome ETF	3.32%	24.84%	1.10%	3.71%	-10.83%	1.54%	25.66%	18.65%	-0.19%	22.28%
ALKS Alkermes plc	58.54%	-2.71%	3.68%	6.16%	12.34%	16.59%	-2.21%	-30.87%	-46.08%	-1.53%

Correlation

The correlation between PBE and ALKS is 0.48, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.48
Correlation (3Y) Calculated over the trailing 3-year period	0.51
Correlation (5Y) Calculated over the trailing 5-year period	0.53
Correlation (10Y) Calculated over the trailing 10-year period	0.56
Correlation (All Time) Calculated using the full available price history since Jun 23, 2005	0.60

The correlation between PBE and ALKS shifts across timeframes, from 0.48 (1 year) to 0.60 (all time), reflecting how their relationship changes across market environments.

Return for Risk

PBE vs. ALKS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PBE

PBE Risk / Return Rank: 58
PBE Sharpe Ratio Rank: 58
PBE Sortino Ratio Rank: 63
PBE Omega Ratio Rank: 53
PBE Calmar Ratio Rank: 63
PBE Martin Ratio Rank: 52

ALKS

ALKS Risk / Return Rank: 76
ALKS Sharpe Ratio Rank: 77
ALKS Sortino Ratio Rank: 75
ALKS Omega Ratio Rank: 73
ALKS Calmar Ratio Rank: 78
ALKS Martin Ratio Rank: 76

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PBE vs. ALKS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Invesco Dynamic Biotechnology & Genome ETF (PBE) and Alkermes plc (ALKS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	PBE	ALKS	Difference
Sharpe ratio: Return per unit of total volatility	1.81	1.20	+0.60
Sortino ratio: Return per unit of downside risk	2.68	1.92	+0.77
Omega ratio: Gain probability vs. loss probability	1.31	1.24	+0.07
Calmar ratio: Return relative to maximum drawdown	2.92	2.21	+0.72
Martin ratio: Return relative to average drawdown	8.21	5.11	+3.10

PBE vs. ALKS - Sharpe Ratio Comparison

The current PBE Sharpe Ratio is 1.81, which is higher than the ALKS Sharpe Ratio of 1.20. The chart below compares the historical Sharpe Ratios of PBE and ALKS, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

PBE vs. ALKS - Drawdown Comparison

The maximum PBE drawdown since its inception was -45.69%, smaller than the maximum ALKS drawdown of -96.14%. Use the drawdown chart below to compare losses from any high point for PBE and ALKS.

Drawdown Indicators

	PBE	ALKS	Difference
Max Drawdown Largest peak-to-trough decline	-45.69%	-96.14%	+50.45%
Max Drawdown (1Y) Largest decline over 1 year	-11.73%	-22.20%	+10.47%
Max Drawdown (3Y) Largest decline over 3 years	-22.43%	-31.58%	+9.15%
Max Drawdown (5Y) Largest decline over 5 years	-34.71%	-33.18%	-1.53%
Max Drawdown (10Y) Largest decline over 10 years	-37.84%	-80.58%	+42.74%
Current Drawdown Current decline from peak	-1.00%	-54.76%	+53.76%
Average Drawdown Average peak-to-trough decline	-16.21%	-67.23%	+51.02%
Ulcer Index Depth and duration of drawdowns from previous peaks	4.17%	9.55%	-5.38%

Volatility

PBE vs. ALKS - Volatility Comparison

The current volatility for Invesco Dynamic Biotechnology & Genome ETF (PBE) is 6.04%, while Alkermes plc (ALKS) has a volatility of 10.43%. This indicates that PBE experiences smaller price fluctuations and is considered to be less risky than ALKS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	PBE	ALKS	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.04%	10.43%	-4.39%
Volatility (6M) Calculated over the trailing 6-month period	13.67%	30.28%	-16.61%
Volatility (1Y) Calculated over the trailing 1-year period	19.01%	40.79%	-21.78%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	22.48%	37.33%	-14.85%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	24.91%	41.31%	-16.40%

Dividends

PBE vs. ALKS - Dividend Comparison

PBE's dividend yield for the trailing twelve months is around 1.02%, while ALKS has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
ALKS Alkermes plc	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
PBE Invesco Dynamic Biotechnology & Genome ETF	1.02%	1.00%	0.05%	0.02%	0.00%	0.00%	0.04%	0.00%	0.00%	0.57%	0.38%	1.12%

Frequently Asked Questions

Can I hold both PBE and ALKS in my portfolio?

PBE and ALKS have a correlation of 0.48, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, PBE or ALKS?

ALKS has higher volatility (10.43%) compared to PBE (6.04%). In terms of maximum drawdown, PBE dropped -45.69% vs ALKS's -96.14%.

Which has better risk-adjusted returns?

PBE currently has the higher Sharpe Ratio (1.81 vs 1.20), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.